Compass Rose Asset Management LP Increases Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Compass Rose Asset Management LP raised its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 150.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 250,000 shares of the company’s stock after buying an additional 150,000 shares during the quarter. Sana Biotechnology comprises 0.2% of Compass Rose Asset Management LP’s holdings, making the stock its 14th largest position. Compass Rose Asset Management LP owned 0.11% of Sana Biotechnology worth $408,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Cerity Partners LLC purchased a new position in shares of Sana Biotechnology in the 4th quarter valued at approximately $25,000. Tower Research Capital LLC TRC increased its stake in Sana Biotechnology by 229.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after purchasing an additional 10,548 shares in the last quarter. Syon Capital LLC acquired a new stake in shares of Sana Biotechnology during the fourth quarter worth $27,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Sana Biotechnology during the third quarter valued at $29,000. Finally, Ameriprise Financial Inc. purchased a new position in Sana Biotechnology in the 4th quarter worth $29,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Trading Down 8.6 %

Shares of SANA opened at $1.71 on Wednesday. The firm has a market cap of $385.57 million, a P/E ratio of -1.22 and a beta of 1.75. The stock’s 50 day moving average is $1.98 and its two-hundred day moving average is $2.52. Sana Biotechnology, Inc. has a 12 month low of $1.26 and a 12 month high of $10.23.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. Equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on SANA shares. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Sana Biotechnology in a research report on Thursday, April 24th. Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a report on Tuesday, March 18th. Finally, Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They issued a “buy” rating and a $7.00 price target on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.